Long-term follow-up study of patients with adrenal incidentalomas. 2002

Rossella Libè, and Chiara Dall'Asta, and Laura Barbetta, and Andrea Baccarelli, and Paolo Beck-Peccoz, and Bruno Ambrosi
Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS, Milan, Italy.

BACKGROUND The incidence of adrenal incidentalomas has sharply increased in recent decades and concurrent subtle endocrine abnormalities, or even subclinical conditions, have been identified. Nonetheless, data concerning possible changes in adrenal size and/or hormonal pattern during follow-up are still inadequate. OBJECTIVE To evaluate long-term morphological and functional evolution of adrenal incidentalomas after initial diagnosis and to identify possible risk factors for hormonal hyperactivity and mass enlargement. METHODS Sixty-four patients (34-79 years) were followed-up for 12-120 months (median 25.5 months). Initial computerized tomography scan showed a unilateral mass in 51 patients and bilateral lesions in 13 patients. Average mass diameter at diagnosis was 2.5+/-0.1 cm (range 1.0-4.0). Twelve patients had subclinical Cushing's syndrome, 41 had mild hormonal alterations, and 11 had normal adrenal function at baseline. All patients were investigated by morphological and functional evaluation 6 and 12 months after diagnosis, and then at 1-year intervals. RESULTS During follow-up, a mass size increase >/=1 cm was observed in 13 patients, and 18 developed further subtle endocrine alterations. Cumulative risk of developing endocrine abnormalities was 17% at 1 year, 29% at 2 years, and 47% at 5 years. The risk was higher in the first 2 years of follow-up if the initial tumor diameter was >or=3 cm. Overall, cumulative risk of mass enlargement was 6% at 1 year, 14% at 2 years, and 29% at 5 years, and it was greater in patients with normal adrenal function than in those with subtle hormonal abnormalities (P<0.05). One female subject showed a mass enlargement after 6 months of follow-up and was eventually diagnosed with non-Hodgkin's lymphoma. CONCLUSIONS Patients with an adrenal incidentaloma are at risk for tumor growth and development of hormonal alterations. The risk of adrenal malignancy, although not elevated, also indicates the need for long-term follow-up.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003480 Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. Cushing's Syndrome,Hypercortisolism,Syndrome, Cushing,Syndrome, Cushing's
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000310 Adrenal Gland Neoplasms Tumors or cancer of the ADRENAL GLANDS. Adrenal Cancer,Adrenal Gland Cancer,Adrenal Neoplasm,Cancer of the Adrenal Gland,Neoplasms, Adrenal Gland,Adrenal Cancers,Adrenal Gland Cancers,Adrenal Gland Neoplasm,Adrenal Neoplasms,Cancer, Adrenal,Cancer, Adrenal Gland,Cancers, Adrenal,Cancers, Adrenal Gland,Neoplasm, Adrenal,Neoplasm, Adrenal Gland,Neoplasms, Adrenal

Related Publications

Rossella Libè, and Chiara Dall'Asta, and Laura Barbetta, and Andrea Baccarelli, and Paolo Beck-Peccoz, and Bruno Ambrosi
March 2014, The Journal of clinical endocrinology and metabolism,
Rossella Libè, and Chiara Dall'Asta, and Laura Barbetta, and Andrea Baccarelli, and Paolo Beck-Peccoz, and Bruno Ambrosi
April 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
Rossella Libè, and Chiara Dall'Asta, and Laura Barbetta, and Andrea Baccarelli, and Paolo Beck-Peccoz, and Bruno Ambrosi
February 1999, The Journal of clinical endocrinology and metabolism,
Rossella Libè, and Chiara Dall'Asta, and Laura Barbetta, and Andrea Baccarelli, and Paolo Beck-Peccoz, and Bruno Ambrosi
May 2009, Clinical endocrinology,
Rossella Libè, and Chiara Dall'Asta, and Laura Barbetta, and Andrea Baccarelli, and Paolo Beck-Peccoz, and Bruno Ambrosi
February 2015, BMC endocrine disorders,
Rossella Libè, and Chiara Dall'Asta, and Laura Barbetta, and Andrea Baccarelli, and Paolo Beck-Peccoz, and Bruno Ambrosi
March 2005, British journal of cancer,
Rossella Libè, and Chiara Dall'Asta, and Laura Barbetta, and Andrea Baccarelli, and Paolo Beck-Peccoz, and Bruno Ambrosi
October 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
Rossella Libè, and Chiara Dall'Asta, and Laura Barbetta, and Andrea Baccarelli, and Paolo Beck-Peccoz, and Bruno Ambrosi
April 2010, European journal of endocrinology,
Rossella Libè, and Chiara Dall'Asta, and Laura Barbetta, and Andrea Baccarelli, and Paolo Beck-Peccoz, and Bruno Ambrosi
January 2021, Endocrine,
Rossella Libè, and Chiara Dall'Asta, and Laura Barbetta, and Andrea Baccarelli, and Paolo Beck-Peccoz, and Bruno Ambrosi
September 2013, The Korean journal of internal medicine,
Copied contents to your clipboard!